D-0633-2022 Class I Terminated

Recalled by STAQ Pharma, Inc. — Denver, CO

FDA drug recall D-0633-2022 was initiated by STAQ Pharma, Inc. on Feb 3, 2022 and is designated Class I. Reason for recall: Labeling: Label Mix up; A limited number of syringes containing HYDROmorphone HCl PF were incorrectly labeled as Morphine Sulfate PF with lot number 21104221A The recall status is terminated (terminated Sep 16, 2022). Affected quantity: 905 Syringes.

Recall details

Product Type
Drugs
Report Date
Feb 23, 2022
Initiation Date
Feb 3, 2022
Termination Date
Sep 16, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
905 Syringes

Product description

HYDROmorphone HCl PF 10 mg/50 mL (0.2mg/mL) in NaCl, 50 mL in 50 mL Single Dose Syringe, Rx only, STAQ Pharma, Inc., Denver, CO 80239, NDC: 73177-0104-05.

Reason for recall

Labeling: Label Mix up; A limited number of syringes containing HYDROmorphone HCl PF were incorrectly labeled as Morphine Sulfate PF with lot number 21104221A

Distribution pattern

CO, OH, and TX.

Code information

Lot Number: 21104221A, Expiration date: 05-22-2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0633-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0633-2022. Report a data issue: hello@regdatalab.com.